Erratum to: Ocular changes in TgF344-AD rat model of alzheimer's disease (Invest Ophthalmol Vis Sci. (2014), 55, (523-534), 10.1167/iovs.13-12888);Ocular changes in TGF344-AD rat model of Alzheimer's disease

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 1, 2014, Pages 523-534

  Tsai, Yuchun ^a   Lu, Bin ^a   Ljubimov, Alexander V ^a,b   Girman, Sergey ^a   Ross Cisneros, Fred N ^c   Sadun, Alfredo A ^c   Svendsen, Clive N ^a,b   Cohen, Robert M ^d   Wang, Shaomei ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Choroidal thickness; Retinal pigment epithelium; Visual acuity

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT COMPONENT C3;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CELL STRUCTURE; CHOROIDAL THICKNESS; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EYE DISEASE; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; TRANSGENIC RAT; VERY ELDERLY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

EID: 84893157398     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12888b     Document Type: Erratum

References (94)

1. Batsch NL, Mittelman MS, eds. World Alzheimer Report 2012: Overcoming the Stigma of Dementia. London: Alzheimer's Disease International; 2012:75.
2. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1.
3. Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol. 1989;34:31-43.
4. Uhlmann RF, Larson EB, Koepsell TD, Rees TS, Duckert LG. Visual impairment and cognitive dysfunction in Alzheimer's disease. J Gen Intern Med. 1991;6:126-132.
5. Cronin-Golomb A, Corkin S, Rizzo JF, Cohen J, Growdon JH, Banks KS. Visual dysfunction in Alzheimer's disease: relation to normal aging. Ann Neurol. 1991;29:41-52.
6. Pache M, Smeets CH, Gasio PF, et al. Colour vision deficiencies in Alzheimer's disease. Age Ageing. 2003;32:422-426.
7. Gilmore GC, Wenk HE, Naylor LA, Koss E. Motion perception and Alzheimer's disease. J Gerontol. 1994;49:P52-P57.
8. Armstrong RA. Visual field defects in Alzheimer's disease patients may reflect differential pathology in the primary visual cortex. Optom Vis Sci. 1996;73:677-682.
9. Trick GL, Trick LR, Morris P, Wolf M. Visual field loss in senile dementia of the Alzheimer's type. Neurology. 1995;45:68-74.
10. Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res. 1989;501: 364-372.
11. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging. 1996;17:377-384.
12. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med. 1986;315: 485-487.
13. Hedges TR, Perez Galves R, Speigelman D, Barbas NR, Peli E, Yardley CJ. Retinal nerve fiber layer abnormalities in Alzheimer's disease. Acta Ophthalmol Scand. 1996;74:271-275.
14. Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg. 2011;113: 523-526.
15. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmology. 1990;97:9-17.
16. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci. 2007;48:2285-2289.
17. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol. 1987;104:113-120.
18. London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9:44-53.
19. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Ab peptide: the many roads to perdition. Neuron. 2004;43:605-608.
20. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem. 2004;89:807-811.
21. Chalbot S, Zetterberg H, Blennow K, et al. Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. J Alzheimers Dis. 2011;25:505-515.
22. Zlokovic BV, Martel CL, Matsubara E, et al. Glycoprotein 330/ megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospi-nal fluid barriers. Proc Natl Acad Sci U S A. 1996;93:4229-4234.
23. Braidy N, Munõz P, Palacios AG, et al. Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm. 2012;119:173-195.
24. Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S. Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci. 2009;50:793-800.
25. Liu B, Rasool S, Yang Z, et al. Amyloid-peptide vaccinations reduce beta-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol. 2009;175:2099-2110.
26. Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-b deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci. 2008;49:5136-5143.
27. Cohen RM, Rezai-Zadeh K, Weitz TM, et al. A Transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric Ab, and frank neuronal loss. J Neurosci. 2013;33:6245-6256.
28. Lu B, Morgans CW, Girman S, et al. Neural stem cells derived by small molecules preserve vision. Transl Vis Sci Technol. 2013;2:1.
29. Girman SV, Lund RD. Most superficial sublamina of rat superior colliculus: neuronal response properties and correlates with perceptual figure-ground segregation. J Neurophysiol. 2007; 98:161-177.
30. Wang S, Lu B, Girman S, et al. Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology. PLoS One. 2010;5:e9200.
31. Jehle T, Wingert K, Dimitriu C, et al. Quantification of ischemic damage in the rat retina: a comparative study using evoked potentials, electroretinography, and histology. Invest Ophthal-mol Vis Sci. 2008;49:1056-1064.
32. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, de Jong PT. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35:2857-2864.
33. Grieshaber P, Lagrèze WA, Noack C, Boehringer D, Biermann J. Staining of Fluorogold-prelabeled retinal ganglion cells with calcein-AM: a new method for assessing cell vitality. J Neurosci Methods. 2010;192:233-239.
34. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389-404.
35. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
36. Thioflavin T Stain: an easier and more sensitive method for amyloid detection. In Picken MM, Herrera GA, eds. Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations. New York: Humana Press; 2012:187-189.
37. Simó R, Villarroel M, Corraliza L, Hernández C, Garcia-Ramírez M. The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. J Biomed Biotechnol. 2010;2010:190724.
38. Liu B, Rasool S, Yang Z, et al. Amyloid-peptide vaccinations reduce fS-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol. 2009;175:2099-2110.
39. Iseri PK, Altinas O, Tokay T, Yüksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neurooph-thalmol. 2006;26:18-24.
40. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17:385-395.
41. Roque RS, Caldwell RB. Muller cell changes precede vascularization of the pigment epithelium in the dystrophic rat retina. Glia. 1990;3:464-475.
42. DiLoreto DA, Martzen MR, del Cerro C, Coleman PD, del Cerro M. Muller cell changes precede photoreceptor cell degeneration in the age-related retinal degeneration of the Fischer 344 rat. Brain Res. 1995;698:1-14.
43. Tanihara H, Hangai M, Sawaguchi S, et al. Up-regulation of glial fibrillary acidic protein in the retina of primate eyes with experimental glaucoma. Arch Ophthalmol. 1997;115:752-756.
44. Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939-945.
45. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54(suppl 1):S204-S217.
46. Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog Retin Eye Res. 2012; 31:377-406.
47. Vincent SJ, Collins MJ, Read SA, Carney LG. Retinal and choroidal thickness in myopic anisometropia. Invest Ophthalmol Vis Sci. 2013;54:2445-2456.
48. Fujiwara T, Imamura Y, Margolis R, Slakter JS, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol. 2009;148: 445-450.
49. Yin ZQ, Vaegan, Millar TJ, Beaumont P, Sarks S. Widespread choroidal insufficiency in primary open-angle glaucoma. J Glaucoma. 1997;6:23-32.
50. Usui S, Ikuno Y, Miki A, Matsushita K, Yasuno Y, Nishida K. Evaluation of the choroidal thickness using high-penetration optical coherence tomography with long wavelength in highly myopic normal-tension glaucoma. Am J Ophthalmol. 2012; 153:10-16.e11.
51. Querques G, Lattanzio R, Querques L, et al. Enhanced depth imaging optical coherence tomography in type 2 diabetes. Invest Ophthalmol Vis Sci. 2012;53:6017-6024.
52. Esmaeelpour M, Brunner S, Ansari-Shahrezaei S, et al. Choroidal thinning in diabetes type 1 detected by 3-dimensional 1060 nm optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53:6803-6809.
53. Kim JH, Kim JR., Kang Se W, Kim SJ, Ha HS. Thinner choroid and greater Drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. Am J Ophthalmol. 2013;155:743-749.e742.
54. Jirarattanasopa P, Ooto S, Nakata I, et al. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vascul-opathy Invest Ophthalmol Vis Sci. 2012;53:3663-3672.
55. Spaide RF. Age-related choroidal atrophy. Am J Ophthalmol. 2009;147:801-810.
56. Scheibel AB. Changes in brain capillary structure in aging and dementia. In: Wertheimer J, Marois M, eds. Senile Dementia Outlook for the Future. New York: Alan R. Liss, Inc.; 1984: 137-149.
57. Miyakawa T, Shimoji A, Kuramoto R, Higuchi Y. The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production. Virchows Arch B Cell Pathol Incl Mol Pathol. 1982;40:121-129.
58. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105:3587-3592.
59. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009;147:811-815.
60. Manjunath V, Taha M, Fujimoto JG, Duker JS. Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol. 2010;150:325-329.e321.
61. Ding X, Li J, Zeng J, et al. Choroidal thickness in healthy Chinese subjects. Invest Ophthalmol Vis Sci. 2011;52:9555-9560.
62. Ayton LN, Guymer RH, Luu CD. Choroidal thickness profiles in retinitis pigmentosa. Clin Experiment Ophthalmol. 2013;41: 396-403.
63. Wang N-K, Lai C-C, Chou CL, et al. Choroidal thickness and biometric markers for the screening of lacquer cracks in patients with high myopia. PLoS One. 2013;8:e53660.
64. Gnana-Prakasam JP, Thangaraju M, Liu K, et al. Absence of iron-regulatory protein Hfe results in hyperproliferation of retinal pigment epithelium: role of cystine/glutamate exchanger. Biochem J. 2009;424:243-252.
65. Hadziahmetovic M, Dentchev T, Song Y, et al. Ceruloplasmin/ hephaestin knockout mice model morphologic and molecular features of AMD. Invest Ophthalmol Vis Sci. 2008;49:2728-2736.
66. Chen H, Lukas TJ, Du N, Suyeoka G, Neufeld AH. Dysfunction of the retinal pigment epithelium with age: increased iron decreases phagocytosis and lysosomal activity. Invest Oph-thalmol Vis Sci. 2009;50:1895-1902.
67. Zhao C, Yasumura D, Li X, et al. Mtor-mediated dedifferen-tiation of the retinal pigment epithelium initiates photorecep-tor degeneration in mice. J Clin Invest. 2011;121:369-383.
68. Bruban J, Glotin AL, Dinet V, et al. Amyloid-b(1-42) alters structure and function of retinal pigmented epithelial cells. Aging Cell. 2009;8:162-177.
69. Coleman HR, Chan CC, Ferris FL, Chew EY. Age-related macular degeneration. Lancet. 2008;372:1835-1845.
70. De S, Rabin DM, Salero E, Lederman PL, Temple S, Stern JH. Human retinal pigment epithelium cell changes and expression of aB-crystallin: a biomarker for retinal pigment epithelium cell change in age-related macular degeneration. Arch Ophthalmol. 2007;125:641-645.
71. Prusky GT, Harker KT, Douglas RM, Whishaw IQ. Variation in visual acuity within pigmented, and between pigmented and albino rat strains. Behav Brain Res. 2002;136:339-348.
72. Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med. 2010;77:69-81.
73. Damiani D, Novelli E, Mazzoni F, Strettoi E. Undersized dendritic arborizations in retinal ganglion cells of the rd1 mutant mouse: a paradigm of early onset photoreceptor degeneration. J Comp Neurol. 2012;520:1406-1423.
74. Williams PA, Thirgood RA, Oliphant H, et al. Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34:1799-1806.
75. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461-467.
76. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72:56-62.
77. Cacquevel M, Lebeurrier N, Chéenne S, Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets. 2004;5:529-534.
78. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12: 1005-1015.
79. D'Andrea MR, Cole GM, Ard MD. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging. 2004;25:675-683.
80. Liao Y-F, Wang B-J, Cheng H-T, Kuo L-H, Wolfe MS. Tumor necrosis factor-a, interleukin-1b, and interferon-c stimulate c-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem. 2004;279:49523-49532.
81. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918-934.
82. Weldon DT, Rogers SD, Ghilardi JR, et al. Fibrillar b-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci. 1998;18:2161-2173.
83. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56:259-262.
84. Loeffler DA, Camp DM, Bennett DA. Plaque complement activation and cognitive loss in Alzheimer's disease. J Neuro-inflammation. 2008;5:9.
85. Rogers J, Cooper NR, Webster S, et al. Complement activation by b-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1992;89:10016-10020.
86. Fonseca MI, Chu SH, Berci AM, et al. Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroinflam-mation. 2011;8:4.
87. Spaide RF, Koizumi H, Pozzoni MC, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146:496-500.
88. Dhoot DS, Huo S, Yuan A, et al. Evaluation of choroidal thickness in retinitis pigmentosa using enhanced depth imaging optical coherence tomography. Br J Ophthalmol. 2013;97:66-69.
89. Sim DA, Keane PA, Mehta H, et al. Repeatability and reproducibility of choroidal vessel layer measurements in diabetic retinopathy using enhanced depth optical coherence tomography. Invest Ophthalmol Vis Sci. 2013;54:2893-2901.
90. Querques G, Lattanzio R, Querques L, et al. Enhanced depth imaging optical coherence tomography in type 2 diabetes. Invest Ophthalmol Vis Sci. 2012;53:6017-6024.
91. Tan CS, Ouyang Y, Ruiz H, Sadda SR. Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Oph-thalmol Vis Sci. 2012;53:261-266.
92. Chakraborty R, Read SA, Collins MJ. Diurnal variations in axial length, choroidal thickness, intraocular pressure, and ocular biometrics. Invest Ophthalmol Vis Sci. 2011;52:5121-5129.
93. Wisdom BJ, Gunwar S, Hudson MD, Noelken ME, Hudson BG. Type IV collagen of Engelbreth-Holm-Swarm tumor matrix: identification of constituent chains. Connect Tissue Res. 1992; 27:225-234.
94. Chen L, Miyamura N, Ninomiya Y, Handa JT. Distribution of the collagen IV isoforms in human Bruch's membrane. Br J Ophthalmol. 2003;87:212-215.